Testicular Cancer

  • Michael A. GarciaEmail author
  • Alexander R. Gottschalk


This chapter will discuss workup, staging, and management of seminoma and non-seminomatous germ cell tumors of the testes.


Testicular cancer Seminoma Non-seminomatous germ cell tumor Germ cell tumor AFP Beta-HCG Orchiectomy Surveillance Radiation Chemotherapy 



We thank Brian Missett MD for his work on the prior edition of this chapter.


  1. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.Google Scholar
  2. Aparicio J, Maroto P, García del Muro X, et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol. 2014;25(11):2173–8.CrossRefGoogle Scholar
  3. Chung PW, Daugaard G, Tyldesley S, et al. Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study. J Clin Oncol. 2010;28:15s. (suppl; abstr 4535)Google Scholar
  4. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  5. Fossa SD, Horwich A, Russell JM, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol. 1999;17:1146.CrossRefGoogle Scholar
  6. Horwich A, Fosså SD, Huddart R, et al. Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br J Cancer. 2014;110(1):256–63.CrossRefGoogle Scholar
  7. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. JCO. 1997;15(2):594–603.CrossRefGoogle Scholar
  8. Jones WG, Fossa SD, Mead GM, et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J Clin Oncol. 2005;23:1200–8.CrossRefGoogle Scholar
  9. Kollmannsberger C, Tandstad T, Bedard PL, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol. 2015;33(1):51–7.CrossRefGoogle Scholar
  10. Mortensen MS, Lauritsen J, Gundgaard MG, et al. A nationwide cohort study of stage I seminoma patients followed on a surveillance program. Eur Urol. 2014;66(6):1172–8.CrossRefGoogle Scholar
  11. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Testicular cancer. Available at: Accessed 10 Jan 2017.
  12. Oliver RTD, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomized trial. Lancet. 2005;266:293–300.CrossRefGoogle Scholar
  13. Oliver RT, Mead GM, Fogarty PJ, et al. Radiotherapy vs carboplatin for stage I seminoma: updated analysis of the MRC/EORTC randomized trial. J Clin Oncol. 2008;26:abstr 1.Google Scholar
  14. Oliver RTD, Mead GM, Rustin GJS, et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011;29(8):957–62.CrossRefGoogle Scholar
  15. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97:1354–65.CrossRefGoogle Scholar
  16. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002;20:4448–52.CrossRefGoogle Scholar
  17. Wilder RB, Buyyounouski MK, Efstathiou JA, Beard CJ. Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biol Phys. 2012;83(4):e445–52.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Radiation Oncology, University of California San FranciscoSan FranciscoUSA
  2. 2.Department of Radiation OncologyUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations